FDA-Approved Weight Loss Medications in Gulfport, MS

 

Phentermine In Gulfport, MS

 
Phentermine HCL is the generic form of an appetite suppressant drug, Adipex, approved by the FDA in 1959. In recent years, it is most often prescribed by Obesity Medicine specialists in conjunction with nutritional intervention and lifestyle modification to aid patients suffering from the chronic medical conditions of Overweight and Obesity and their associated comorbidities.
 
 

 

Qsymia®

Qsymia® (phentermine and topiramate extended-release) capsules CIV
Qsymia® is an FDA-approved prescription medicine that may help some obese adults or some overweight adults who also have weight-related medical problems lose weight and keep the weight off.
Qsymia® should be used with a reduced-calorie diet and increased physical activity.
QSYMIA® (phentermine and topiramate extended-release) capsules CIV VS PLACEBO FOR ONE YEAR OF TREATMENT (P<0.0001)
2,487 overweight or obese patients (BMI 27 or greater and less than or equal to 45) with 2 or more weight-related comorbidities were evaluated.
 
 
 
 
 

Belviq®

 
Belviq® is part of the Central Nervous System Stimulants class and treats Weight Loss. Central nervous system stimulants are used as an aid in weight loss by increasing certain activity in the brain to speed up mental and physical processes.
Belviq® helps overweight people with type 2 diabetes lose weight. Belviq® was also tested in a study involving 604 overweight men and women with type 2 diabetes. Results showed that more than a third of people taking Belviq® with diet and exercise (37.5%) lost 5% or more of their body weight, compared with those using diet and exercise alone (16.1%). In the same study, the Belviq® group showed significant improvements in blood sugar levels, compared with those using diet and exercise alone.
Belviq® is an FDA-approved prescription weight-loss medication that, when used with diet and exercise, can help some overweight adults with a weight-related medical problem, or obese adults, lose weight and keep it off.
 
 
Belviq® can help you lose weight and improve certain health risk factors — In FDA clinical trials, people who added Belviq® to diet and exercise were able to lose weight and improve health risk factors, such as high blood pressure, high blood sugar, and high cholesterol levels. Belviq® was tested in two major clinical studies, one lasting a year (4,008 people) and one lasting 2 years (3,182 people).*
The combined results of these two studies showed that:
  • Almost half of people (47.1%) taking Belviq® lost 5% or more of their body weight after 1 year of treatment, compared with those using diet and exercise alone (22.6%)
  • Some (22.4%) lost as much as 10% of their body weight after 1 year of treatment, compared with those using diet and exercise alone (8.7%)
People taking Belviq® with diet and exercise had significant improvements in their blood pressure and cholesterol levels, compared to those using diet and exercise alone. It is not known if Belviq® changes your risk of heart problems, stroke, or death due to heart problems or stroke.
Belviq® can help you manage your weight loss — In a major clinical trial, people taking Belviq® were able to lose weight and maintain weight loss up to 2 years. In the 2-year study, almost half of people who completed the first year continued on in year 2. All people regained weight but remained below their starting weight.

Contrave®

CONTRAVE is a prescription medicine that contains 2 medicines (naltrexone HCl and bupropion HCl) that may help some obese adults, or overweight adults* who also have weight-related medical problems†, lose weight and keep the weight off.
Contrave® is part of the Opioid Antagonist / Atypical Antidepressant Combinations class and treats Weight Loss. Opioid antagonist / atypical antidepressant combination drugs are used in combination with diet and exercise to help with weight loss in obese or overweight patients. They work by decreasing appetite and food intake.
 
 
 
 

 

September 2014 Press Release

Deerfield, Ill., and La Jolla, Calif., September 11, 2014 – Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. (Nasdaq: OREX) jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

Primary and Secondary Outcomes for Participants Completing 56 Weeks Of Contrave Therapy in Two Trials

Change in body weight (%)–1.8%–6.7%–8.1%–7.3%–11.5%
Change in body weight (kg)–1.9–6.5–8.0
Participants with a weight loss of 5% or more67 (23%)155 (55%)183 (62%)60.4%80.4%
Participants with a weight loss of 10% or more31 (11%)85 (30%)102 (34%)30.2%55.2%
Participants with a weight loss of 15% or more9 (3%)40 (14%)51 (17%)17.9%39.5%
NBSR = naltrexone SR/bupropion SR combination.
The dose of naltrexone SR is noted in the table (16 and 32 mg). The dose of bupropion SR is fixed at 360 mg/day.
*For all comparisons, P < 0.0001 compared with placebo.
†For all comparisons, P < 0.001.
 

Book An Appointment

Health Fit M.D. provides medical weight loss and aesthetic procedures for clients all over the Mississippi Gulf Coast. Call (228) 206-0542 or book an appointment online with our Medical Weight Loss Doctor or Licensed Aesthetician today!
Also Serving: D'Iberville, MS, Bay Saint Louis, MS, Diamondhead, MS, Biloxi, MS, Long Beach, MS, Pass Christian, MS, Ocean Springs, MS, Gautier, MS, Pascagoula, MS, Saucier, MS, Wiggins, MS, Waveland, MS